Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock [Yahoo! Finance]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Yahoo! Finance
On March 19, Truist began coverage of Altimmune Inc. (NASDAQ:ALT) with a $12 price target, leading to a whopping 315% upside potential at the prevailing level. The firm also assigned a Buy rating to the stock. Pressmaster/Shutterstock.com According to Truist, Altimmune's primary product pemividutide may have a chance to succeed in the treatment of MASH, along with liver-related disorders, such as AUD. Based on its model, Truist estimates peak adjusted or unadjusted revenue at around $600 million-$1 billion with 20,000 patients receiving pemividutide treatment. This makes it one of the most attractive penny stock names with heavy short interest lately. Back on March 16, H.C. Wainwright also reaffirmed its Buy rating for Altimmune Inc. (NASDAQ:ALT) while substantially increasing its price target from $12 to $25. The firm attributed this to the company's focus on its upcoming MASH pivotal program, along with the significant short-term gains from focused efforts to combat alcohol-r
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of SecuritiesGlobeNewswire
- Altimmune (ALT) was upgraded by The Goldman Sachs Group, Inc. from "buy" to "neutral".MarketBeat
- Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of SecuritiesGlobeNewswire
- Altimmune Announces Proposed Underwritten Public Offering of SecuritiesGlobeNewswire
- Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M [Yahoo! Finance]Yahoo! Finance
ALT
Earnings
- 3/5/26 - Miss
ALT
Sec Filings
- 4/24/26 - Form 8-K
- 4/24/26 - Form 424B5
- 4/22/26 - Form S-3MEF
- ALT's page on the SEC website